lovo-cel

GENE THERAPY | FDA Decision on Lovo-cel for SCD Now Expected by Year’s End

The regulatory agency has agreed to review an application from lovo-cel’s developer, Bluebird Bio, requesting the gene therapy’s approval for SCD patients ages 12 and older. Moreover, the FDA has given the application priority…